

pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group: Lyr	mp	homa	Foun	datio	n (Cana	da
--	----	------	------	-------	-----	------	----

aka Lymphoma Canada

Name of drug and indication under review: Zydelig (idelalisib) in combination with rituximab

for the treatment of patients with relapsed CLL

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. Patient advocacy groups must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the patient advocacy group input.

Examples of conflicts of interest include, but are not limited to:

• financial support from the pharmaceutical industry e.g., educational or research grants, honoraria, gifts, and salary;


Has this patient advocacy group received any payments over the previous two years from any

• affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

•				hat may have direct or indirect interest in the drug under review?
	X	Yes No		
	If no	o, please go to Se	ctio	n B
2.	Wha	t form of paymen	t dic	I this patient advocacy group receive? (Check all that apply.)
		Operating Funds		
	Χ	Program Funding	j (e.	g., website)
		Royalties	Χ	Research/educational grants
		Gifts	Χ	Sponsorship of Events
		Honoraria		Other, please specify:

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.



Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No member of the LFC Board of Directors is in possession of such stocks or options for organizations that may have a direct or indirect interest in the drug under review. As an organization, LFC owns no stocks or options.

Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

One member of the LFC Board of Directors,	, through his role as President,					
Shoppers Drug Mart Specialty Health Network, maintains commercial relationships with numerous						
drug manufacturers, including Gilead, Shoppers Drug Mart Specialty Health Network operates a						
national clinic network to dispense and deliver infusions and injections, and has business operations in importing, distributing, and wholesaling of pharmaceutical products regulated by Health Canada.						
and and a bound of Directors have acted as consultants for Gilead.						

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

April 15th, 2015

Robin Markowitz

Signature: John Markwith